Together, everyone at Synageva shares a passion and commitment to improving the lives of patients suffering from rare diseases.

We believe that Every Second Counts when discovering, developing, and delivering therapies to these patients.
 

Learn More

 

Synageva BioPharma Corp. is a biopharmaceutical company with headquarters, research and development facilities in Lexington, MA. Our mission is to deliver breakthrough medicines globally for patients suffering from rare, devastating diseases. Our team has a proven track record of delivering life-altering therapies to patients with diseases once considered too rare for developing treatments.

Learn More

News & Events

January 26, 2015
Synageva BioPharma Announces Dosing Of Patients Commenced With SBC-103 In Phase 1/2 Study For Mucopolysaccharidosis IIIB And FDA Fast Track Designation Granted

January 12, 2015
Click here to Listen to President and CEO Sanj K. Patel and COO Robert Bazemore's Presentation at the 33rd Annual J.P. Morgan Healthcare Conference

January 6, 2015
Synageva BioPharma Announces Pricing Of Public Offering Of Common Stock

January 5, 2015
Synageva BioPharma Announces New Pipeline Programs And Other Company Progress

December 23, 2014
Synageva BioPharma Announces Sebelipase Alfa Marketing Authorization Application Validated By The EMA

December 17, 2014
Synageva BioPharma To Present At The 33rd Annual J.P. Morgan Healthcare Conference On Monday, January 12, 2015 At 9:00 A.M. PST

December 15, 2014
Synageva BioPharma Announces Active Investigational New Drug Application For SBC-103 For The Treatment Of Mucopolysaccharidosis IIIB

November 10, 2014
Synageva BioPharma Presents New Data From Phase 3 Study Of Sebelipase Alfa In Children And Adults With LAL Deficiency At The AASLD Meeting

October 30, 2014
Synageva BioPharma Reports Third Quarter 2014 Financial Results

October 23, 2014
Synageva BioPharma Presents Sebelipase Alfa Data At The NASPGHAN Meeting

June 30, 2014
Synageva BioPharma Reports Positive Top-Line Results From Phase 3 Study Of Sebelipase Alfa In Children And Adults With LAL Deficiency

June 3, 2014
Synageva BioPharma Highlights Data Presentations and Satellite Symposium at the European Atherosclerosis Society Congress

May 2, 2014
Synageva BioPharma Announces Satellite Symposium At The National Lipid Association Meeting

April 23, 2014
Click here to read the 2013 Annual Report and letter to Shareholders.

April 21, 2014
LAL Deficiency Disease Review Published In Atherosclerosis

March 4, 2014
Synageva BioPharma Issued U.S. Patent for Treatment of LAL Deficiency

February 13, 2014
Synageva Biopharma Highlights Sebelipase Alfa And LAL Deficiency Data At The Lysosomal Disease Network (LDN) World Symposium

February 12, 2014
Synageva Biopharma Highlights SBC-103 Data At The Lysosomal Disease Network (LDN) World Symposium

    More News